Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from cidara therapeutics This provides mundipharma with global ownership of rezafungin including ongoing development and distribution 1 invasive candidiasis, is a severe, life. Mundipharma has signed an agreement to acquire all assets and rights related to antifungal candidate rezzayo (rezafungin) from cidara therapeutics, including ongoing development and distribution The assets and rights will be acquired by napp pharmaceutical group, which is a member of the international network of mundipharma independent associated companies. This provides mundipharma with global ownership of rezafungin including ongoing development and distribution.
Mundipharma currently has commercial rights to rezafungin outside the u.s Mundipharma purchased the assets in consideration of its assumption of the ongoing obligation to conduct and fund the respect phase 3 clinical trial, the costs of the rezafungin patent portfolio and cmc and regulatory obligations.
WATCH
